Floatz logo

Chimeric Antigen Receptor Modified T Cells Infusion

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Daihong LiuCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) cohort.

Asset / SponsorPhaseRating
Tucidinostat
Sun Yat-sen University
Phase 2B
Apg-2575
Sun Yat-sen University
Phase 1/2CCC

Same molecule, other indications

Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:

B Cell LymphomaDormant
BB
Indicative ·
71 / 100
View asset →
Non Hodgkin LymphomaDormant
BB
Indicative ·
67 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →